Evidence map›Paper›PMID 39695090›Full record

ArticleCell death & disease2024

DARPins as a novel tool to detect and degrade p73.

Philipp Münick, Jasmin Zielinski, Alexander Strubel, Niklas Gutfreund, Birgit Dreier, Jonas V Schaefer, Birgit Schäfer, Jakob Gebel, Christian Osterburg, Apirat Chaikuad and 3 more

Abstract read
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Philipp Münick *Institute of Biophysical Chemistry and Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt, Germany.ORCID 0000-0002-0548-0897
Jasmin Zielinski *Institute of Biophysical Chemistry and Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt, Germany.
Alexander Strubel *Institute of Biophysical Chemistry and Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt, Germany.ORCID 0000-0002-8175-962X
Niklas GutfreundInstitute of Biophysical Chemistry and Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt, Germany.
Birgit DreierDepartment of Biochemistry, University of Zurich, 8057, Zurich, Switzerland.
Jonas V SchaeferDepartment of Biochemistry, University of Zurich, 8057, Zurich, Switzerland.ORCID 0000-0002-8332-4371
Birgit SchäferInstitute of Biophysical Chemistry and Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt, Germany.
Jakob GebelInstitute of Biophysical Chemistry and Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt, Germany.
Christian OsterburgInstitute of Biophysical Chemistry and Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt, Germany.
Apirat ChaikuadInstitute of Pharmaceutical Chemistry, Goethe University, 60438, Frankfurt, Germany.
Stefan KnappInstitute of Pharmaceutical Chemistry, Goethe University, 60438, Frankfurt, Germany.ORCID 0000-0001-5995-6494
Andreas PlückthunDepartment of Biochemistry, University of Zurich, 8057, Zurich, Switzerland.ORCID 0000-0003-4191-5306
Volker DötschInstitute of Biophysical Chemistry and Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt, Germany. vdoetsch@em.uni-frankfurt.de.ORCID 0000-0001-5720-212X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The concept of Targeted Protein Degradation (TPD) has been introduced as an attractive alternative to the development of classical inhibitors. TPD can extend the range of proteins that can be pharmacologically targeted beyond the classical targets for small molecule inhibitors, as a binding pocket is required but its occupancy does not need to lead to inhibition. The method is based on either small molecules that simultaneously bind to a protein of interest and to a cellular E3 ligase and bring them in close proximity (molecular glue) or a bi-functional molecule synthesized from the chemical linkage of a target protein-specific small molecule and one that binds to an E3 ligase (Proteolysis Targeting Chimeras (PROTAC)). The further extension of this approach to bioPROTACs, in which a small protein-based binding module is fused directly to an E3 ligase or an E3 ligase adaptor protein, makes virtually all proteins amenable to targeted degradation, as this method eliminates the requirement for binding pockets for small molecules. Designed Ankyrin Repeat Proteins (DARPins) represent a very attractive class of small protein-based binding modules that can be used for the development of bioPTOTACS. Here we describe the characterization of two DARPins generated against the oligomerization domain and the SAM domain of the transcription factor p73, a member of the p53 protein family. The DARPins can be used for (isoform-)selective pulldown experiments both in cell culture as well as primary tissue lysates. We also demonstrate that they can be used for staining in cell culture experiments. Fusing them to the speckle type POZ protein (SPOP), an adaptor protein for cullin-3 E3 ligase complexes, yields highly selective and effective degraders. We demonstrate that selective degradation of the ΔNp73α isoform reactivates p53.

Indexed as

ProteolysisTumor Protein p73HumansProtein BindingTumor Suppressor Protein p53Ubiquitin-Protein LigasesTumor Protein p73Tumor Suppressor Protein p53Ubiquitin-Protein Ligases

Identifiers

PMID39695090
PMCPMC11655841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.